We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Fig. 5

Fig. 5. From: LOCOREGIONAL TREATMENT OUTCOMES AFTER MULTIMODALITY MANAGEMENT OF INFLAMMATORY BREAST CANCER.

Actuarial Grade 3 to 4 complication rates in patients treated to a lower radiation dose of 60 Gy (n = 79) vs. a higher dose of 66 Gy (n = 113).

Ian J. Bristol, et al. Int J Radiat Oncol Biol Phys. ;72(2):474-484.
2.
Fig. 4

Fig. 4. From: LOCOREGIONAL TREATMENT OUTCOMES AFTER MULTIMODALITY MANAGEMENT OF INFLAMMATORY BREAST CANCER.

(Top) Locoregional control (LRC) as a function of age (≤45 years vs. >45 years). (Bottom left) LRC in patients aged ≤45 years as a function of radiation dose (n = 45 for dose 66 Gy, n = 25 for 60 Gy). (Bottom right) LRC in patients aged >45 years as a function of radiation dose (n = 68 for dose 66 Gy, n = 54 for 60 Gy).

Ian J. Bristol, et al. Int J Radiat Oncol Biol Phys. ;72(2):474-484.
3.
Fig. 2

Fig. 2. From: LOCOREGIONAL TREATMENT OUTCOMES AFTER MULTIMODALITY MANAGEMENT OF INFLAMMATORY BREAST CANCER.

(Top) Locoregional control (LRC) as a function of response to neoadjuvant chemotherapy. (Bottom left) LRC in patients who experienced at least a PR to chemotherapy as a function of radiation dose (n = 94 for dose 66 Gy, n = 59 for 60 Gy). (Bottom right) LRC in patients who experienced less than a PR to chemotherapy as a function of radiation dose (n = 14 for dose 66 Gy, n = 16 for 60 Gy).

Ian J. Bristol, et al. Int J Radiat Oncol Biol Phys. ;72(2):474-484.
4.
Fig. 3

Fig. 3. From: LOCOREGIONAL TREATMENT OUTCOMES AFTER MULTIMODALITY MANAGEMENT OF INFLAMMATORY BREAST CANCER.

(Top) Locoregional control (LRC) as a function of surgical margin status. (Bottom left) LRC in patients with negative surgical margins as a function of radiation dose (n = 87 for dose 66 Gy, n = 46 for 60 Gy). (Bottom right) LRC in patients with positive or unknown surgical margins as a function of radiation dose (n = 26 for dose 66 Gy, n = 33 for 60 Gy).

Ian J. Bristol, et al. Int J Radiat Oncol Biol Phys. ;72(2):474-484.
5.
Fig. 1

Fig. 1. From: LOCOREGIONAL TREATMENT OUTCOMES AFTER MULTIMODALITY MANAGEMENT OF INFLAMMATORY BREAST CANCER.

(Top left) Overall survival (OS), locoregional control (LRC), and distant metastasis–free survival (DMFS) in all patients in the series (n = 256). (Top right) OS in patients able to complete combined-modality therapy as intended (group 1, n = 192) vs. OS in patients who did not complete therapy as intended (group 2, n = 64). (Bottom left) LRC as a function of group. (Bottom right) DMFS as a function of group.

Ian J. Bristol, et al. Int J Radiat Oncol Biol Phys. ;72(2):474-484.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk